Patents by Inventor Walter Martin GREGORY

Walter Martin GREGORY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUS
    Publication number: 20240000816
    Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.
    Type: Application
    Filed: April 11, 2023
    Publication date: January 4, 2024
    Inventors: Walter Martin GREGORY, Juan Carlos TERCERO, Robert E. COLEMAN, Roger GOMIS
  • THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUS
    Publication number: 20230381209
    Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid.
    Type: Application
    Filed: February 15, 2023
    Publication date: November 30, 2023
    Inventors: Walter Martin GREGORY, Juan Carlos TERCERO, Roger GOMIS, Robert E. COLEMAN
  • Therapeutic treatment of breast cancer based on c-MAF status
    Patent number: 11654153
    Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: May 23, 2023
    Assignee: INBIOMOTION S.L.
    Inventors: Walter Martin Gregory, Juan Carlos Tercero, Robert E. Coleman, Roger Gomis
  • Therapeutic treatment of breast cancer based on c-MAF status
    Patent number: 11596642
    Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: March 7, 2023
    Assignee: INBIOMOTION S.L.
    Inventors: Walter Martin Gregory, Juan Carlos Tercero, Roger Gomis, Robert E. Coleman
  • THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUS
    Publication number: 20210137952
    Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.
    Type: Application
    Filed: November 21, 2018
    Publication date: May 13, 2021
    Inventors: Walter Martin GREGORY, Juan Carlos TERCERO, Robert E. COLEMAN, Roger GOMIS
  • THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUS
    Publication number: 20190269707
    Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid.
    Type: Application
    Filed: May 25, 2017
    Publication date: September 5, 2019
    Applicant: INBIOMOTION S.L.
    Inventors: Walter Martin GREGORY, Juan Carlos TERCERO, Roger GOMIS, Robert E. COLEMAN